Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Read article at publisher's site DOI : Gil-Bazo I , Rolfo C. Mol Oncol , 13 12 , 30 Sep Sci Rep , 9 1 , 22 Nov

Author:Kajigar Doujind
Language:English (Spanish)
Published (Last):26 January 2014
PDF File Size:18.56 Mb
ePub File Size:13.28 Mb
Price:Free* [*Free Regsitration Required]

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Read article at publisher's site DOI : Gil-Bazo I , Rolfo C.

Mol Oncol , 13 12 , 30 Sep Sci Rep , 9 1 , 22 Nov J Clin Med , 8 8 , 07 Aug Cells , 8 8 , 09 Aug Oncotarget , 10 38 , 04 Jun To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation. Expert Rev Mol Diagn , 16 12 , 27 Oct Cited by 3 articles PMID: Lung Cancer , , 11 Jul Cited by 5 articles PMID: Lung Cancer , 83 3 , 03 Jan Cited by 21 articles PMID: Health Technol Assess , 18 32 , 01 May Cited by 7 articles PMID: BMC Cancer , , 27 Apr Coronavirus: Find the latest articles and preprints.

Europe PMC requires Javascript to function effectively. Recent Activity. Recent history Saved searches. Abstract Available from publisher site using DOI. A subscription may be required. Malapelle U 1 ,. Sirera R 2 ,. Jantus-Lewintre E 2 ,. Search articles by 'Pablo Reclusa'.

Reclusa P 3 ,. Search articles by 'Ana Blasco'. Blasco A 4 ,. Pisapia P 1 ,. Search articles by 'Christian Rolfo'. Rolfo C 3 ,. Camps C 4. Affiliations 2 authors 1. This article has been corrected. See Expert Rev Mol Diagn. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.

Areas covered: The EGFR mutation testing landscape is manifold and includes both screening and targeted methods, each with their own pros and cons. This application will be valuable for laboratories with whose purpose is purely diagnostic and lacking high-throughput technologies.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer EURTAC : a multicentre, open-label, randomised phase 3 trial. EGFR mutation detection by microfluidic technology: a validation study. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Show 10 more references 10 of Smart citations by scite. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles. Explore citation contexts and check if this article has been supported or contradicted. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.

Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA. Epidermal growth factor receptor tyrosine kinase EGFR-TK mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy. I agree, dismiss this banner. Wicket Ajax Debug Window drag me here.


Company News

We also evaluated whether pleural effusion supernatant PE-SUP samples are assayable, similar to plasma samples, using these two kits. In less-dilute samples, accuracy and sensitivity did not differ significantly between kits. PE-SUP samples are assayable using either kit. LeuArg mutation LR [ 1 ]. Despite this transient response, most patients eventually become resistant [ 3 , 4 ]. The secondary p. Although a tissue biopsy is recommended for EGFR mutation testing, the risk of complications during the biopsy, lack of available tumor tissue, and low-quality tissue samples can limit mutation detection.


China's NMPA Extends Approval for Roche Cobas EGFR Mutation Test v2 to Plasma Samples

In normal tissue, the EGFR protein transmits signals in cells to regulate cell growth and cell death. The second version of the test v2 was approved in late The liquid biopsy test performed on plasma can serve to provide a less invasive testing option and overcomes the limitations of tissue biopsy samples. The test uses a sample preparation system called the cobas-cfDNA Sample Preparation kit which provides stabilization of the cfDNA in the collected specimen. The following is a summary of the test: The plasma specimen is prepared using the cobas cfDNA preparation kit which serves to stabilize the cfDNA and prepare the specimen for amplification and detection. Following sample preparation, Roche uses the cobas z system for automated amplification and detection.

Related Articles